Resources
Research
Research summaries from Dr Faizal Secretary, written for patients: what a study actually reported, what it could not show, and what it means for care in the UK.
Sourced · AMA referenced · Fulwood, Preston
Research
Summaries of the Evidence
- Medicines safety
FDA GLP-1 Vision Loss Warning: What Is NAION and What UK Patients Should Know
The FDA’s 9 November 2026 safety communication on NAION and GLP-1 medicines, what the evidence shows, and the MHRA’s UK advice for semaglutide and Mounjaro users.
- Weight management
Retatrutide vs Ozempic: What the Head-to-Head Trial Showed
Topline Phase 3 results from TRANSCEND-T2D-2 on weight, HbA1c and side effects, what the study could not show, and why retatrutide has no UK licence.
Book Today
Ready to Be Seen?
Mon–Thu 5–8pm · Friday 9am–8pm · Saturday 9am–1pm.
Or email: hello@myprivateclinic.co.uk